Anglo-Swedish pharmaceuticals firm AstraZeneca (LSE: AZN) has confirmed it is in talks with Dutch cancer drugmaker Acerta Pharma.
It follows reports last week in the Wall Street Journal that AstraZeneca was prepared to buy Acerta for more than $5 billion.
In a statement, the company said: “Further to recent speculation, AstraZeneca confirms it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze